Emergency Medicine Doctors in West Grove, PA Accepting Medicare

3 Emergency Medicine doctors found. Showing 1 - 3

Dr. Fred Raymond Himmelstein, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1015 W Baltimore Pike, Jennersville Regional Hospital, West Grove, PA 19390 Phone: 610-869-1000    Fax: 610-617-6280

Dr. Scott Andrew Resweber, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1015 W Baltimore Pike, Jennersville Regional Hospital, West Grove, PA 19390 Phone: 610-869-1000    Fax: 610-617-6280

John Oliver Elkhoury, PA Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1015 W Baltimore Pike, West Grove, PA 19390 Phone: 610-869-1000

News Archive

Evidence explains relationship between television and poor diet in children

Researchers from the Harvard School of Public Health (HSPH) and Children's Hospital Boston found that kids who spend more time watching television also eat more of the calorie-dense, low-nutrient foods advertised on television. Previous studies had demonstrated that children who watch more television are more likely to be overweight, but this is the first time a research team has found evidence for a mechanism explaining that relationship.

U.N. calls on countries to develop national drought, climate policies

"The world urgently needs to adopt drought-management policies as farmers from Africa to India struggle with lack of rainfall and the United States endures the worst drought it has experienced in decades, top officials with the U.N. weather agency said Tuesday," the Associated Press reports.

New initiative aims to develop Global Psoriasis Atlas

While studies over the recent years have contributed to an improved understanding of psoriasis, there are still significant gaps in knowledge related to the epidemiology of this serious, chronic disease and trends in incidence over time. The World Health Organization, reported in 2013 that the worldwide prevalence of psoriasis is around 2%, but that studies in developed countries have declared prevalence rates of more than twice the global estimate at an average of 4.6% .

GeoVax requests FDA meeting to discuss IND for its therapeutic HIV/AIDS vaccine

GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that it has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) to discuss a proposed IND for GeoVax's therapeutic vaccine as a treatment for individuals infected with HIV/AIDS.

Read more Medical News

› Verified 7 days ago